IL-11 has now been identified as a driver in a wide range of malignancies, including breast, prostate, endometrial, ovarian, liver, and gastric cancers, and is considered an important biomarker in determining the prognosis of patients with breast, lung, and gastric cancers [30,31,32,33]. Here, IL11 is linked to gastric cancer.